Maria T. Diaz-Meco

Maria T. Diaz-Meco

Auto-generated profile, based on publicly available information

Maria T. Diaz-Meco

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2020 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
JTJelena Todoric
Jelena Todoric
GCGiuseppe Di Caro
Giuseppe Di Caro
SRSaskia Reibe
Saskia Reibe
DHDarren Henstridge
Darren Henstridge
CGCourtney R. Green
Courtney R. Green
MKMichael Karin
Michael Karin

1 October 2017 in Current Opinion in Cell Biology
Verified
Journal Article
Closed access
MRMiguel Reina-Campos
Miguel Reina-Campos
JMJorge Moscat
Jorge Moscat
MDMaria Diaz-Meco
Maria Diaz-Meco

1 October 2016 in Cancer Cell
Verified
Journal Article
Closed access
ADAngeles Duran
Angeles Duran
EHEloy D. Hernandez
Eloy D. Hernandez
MRMiguel Reina-Campos
Miguel Reina-Campos
ECElias A. Castilla
Elias A. Castilla
SSShankar Subramaniam
Shankar Subramaniam
JMJorge Moscat
Jorge Moscat

1 March 2019 in Cancer Cell
Verified
Journal Article
Closed access
MRMiguel Reina-Campos
Miguel Reina-Campos
JLJuan F. Linares
Juan F. Linares
ADAngeles Duran
Angeles Duran
TCThekla Cordes
Thekla Cordes
ALAntoine L'HErmitte
Antoine L'HErmitte
MDMaria T. Diaz-Meco
Maria T. Diaz-Meco

25 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MOMayuki Omatsu
Mayuki Omatsu
YNYuki Nakanishi
Yuki Nakanishi
KIKosuke Iwane
Kosuke Iwane
NANaoki Aoyama
Naoki Aoyama
ADAngeles Duran
Angeles Duran
HSHiroshi Seno
Hiroshi Seno
Mesenchymal activation, characterized by dense stromal infiltration of immune and mesenchymal cells, fuels the aggressiveness of colorectal cancers (CRC), driving progression and metastasis. Targetable molecules in the tumor microenvironment (TME) need to be identified to improve the outcome in CRC patients with this aggressive phenotype. This study reports a positive link between high thrombospondin-1 (THBS1) expression and mesenchymal characteristics, immunosuppression, and unfavorable CRC prognosis. Bone marrow-derived monocyte-like cells recruited by CXCL12 are the primary source of THBS1, which contributes to the development of metastasis by inducing cytotoxic T-cell exhaustion and impairing vascularization. Furthermore, in orthotopically generated CRC models in male mice, THBS1 loss in the TME renders tumors partially sensitive to immune checkpoint inhibitors and anti-cancer drugs. Our study establishes THBS1 as a potential biomarker for identifying mesenchymal CRC and as a critical suppressor of antitumor immunity that contributes to the progression of this malignancy with a poor prognosis.

1 August 2015 in Cell Reports
Verified
Journal Article
Open access
JLJuan F. Linares
Juan F. Linares
ADAngeles Duran
Angeles Duran
MRMiguel Reina-Campos
Miguel Reina-Campos
PAPedro Aza-Blanc
Pedro Aza-Blanc
ACAlex Campos
Alex Campos
MDMaria T. Diaz-Meco
Maria T. Diaz-Meco
The mTORC1 complex is central to the cellular response to changes in nutrient availability. The signaling adaptor p62 contributes to mTORC1 activation in response to amino acids and interacts with TRAF6, which is required for the translocation of mTORC1 to the lysosome and the subsequent K63 polyubiquitination and activation of mTOR. However, the signal initiating these p62-driven processes was previously unknown. Here, we show that p62 is phosphorylated via a cascade that includes MEK3/6 and p38δ and is driven by the PB1-containing kinase MEKK3. This phosphorylation results in the recruitment of TRAF6 to p62, the ubiquitination and activation of mTOR, and the regulation of autophagy and cell proliferation. Genetic inactivation of MEKK3 or p38δ mimics that of p62 in that it leads to inhibited growth of PTEN-deficient prostate organoids. Analysis of human prostate cancer samples showed upregulation of these three components of the pathway, which correlated with enhanced mTORC1 activation.